About
Small Molecules
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Team (18)
BIO: Kura Oncology CEO Wilson on the power of biotech in the quest beyond KRAS
BIO: Kura Oncology CEO Wilson on the power of biotech in the quest beyond KRAS
Kura Oncology
executive
Carol Schafer
Carol Schafer
Kura Oncology
team_member
Diane Parks
Diane Parks
Kura Oncology
team_member
Faheem Hasnain
Faheem Hasnain
Kura Oncology
team_member
Fostering a Workplace Place for Innovators to Thrive
Fostering a Workplace Place for Innovators to Thrive
Kura Oncology
team_member
Helen Collins
Helen Collins, M.D.
Kura Oncology
team_member
Clinical Trials (22)
View allTotal Trials
22
As Lead Sponsor
17
As Collaborator
5
Total Enrollment
3,396
By Phase
PHASE2: 6PHASE3: 1PHASE1: 10PHASE1/PHASE2: 3
By Status
RECRUITING: 10COMPLETED: 4TERMINATED: 3AVAILABLE: 2NOT_YET_RECRUITING: 1WITHDRAWN: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline20 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
Today
Hover over trial bars to see details
Recent Trials
NCT06930352Collaborator
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
PHASE2Not yet recruiting
70 participants
Started: Jan 10, 2026 · Completed: Dec 31, 2027
NCT07007312Lead Sponsor
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
PHASE3Recruiting
1,300 participants
Started: Sep 26, 2025 · Completed: Nov 30, 2031
NCT06655246Lead Sponsor
A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
PHASE1Recruiting
157 participants
Started: Mar 27, 2025 · Completed: Dec 31, 2028
NCT06376162Collaborator
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
PHASE1Recruiting
20 participants
Started: Mar 18, 2025 · Completed: Jan 31, 2027
NCT06448013Collaborator
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
PHASE1Recruiting
22 participants
Started: Mar 7, 2025 · Completed: Dec 31, 2030
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...